Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
We compare patterns of gray matter loss on MRI in subjects presenting as corticobasal syndrome (CBS) with Alzheimer disease pathology (CBS-AD) to those presenting as CBS with corticobasal degeneration pathology (CBS-CBD).
Why it matters
This small study of pathologically confirmed cases compared patterns of gray matter loss on MRI between people with corticobasal syndrome who had Alzheimer disease pathology and those who had corticobasal degeneration pathology. It is about distinguishing these conditions using imaging, not about treating or preventing Alzheimer's disease.
-
The epsilon4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for Alzheimer's disease (AD), but limited work has suggested that APOE genotype may modulate disease phenotype.
-
I coauthored a recently published research article describing a variable length, poly-T polymorphism in the TOMM40 gene, adjacent to apolipoprotein E (APOE) on chromosome 19, that accounts for the age at onset distribution for a complex disease, late-onset Alzheimer disease.
Why it matters
A variable-length repeat in the TOMM40 gene was linked to the age at which late-onset Alzheimer disease begins, with longer repeats tied to earlier onset when inherited with APOE3. This is a genetic observation about timing of disease and does not show how to treat or prevent it.
-
The vascular hypothesis of Alzheimer disease (AD), first proposed by us in 1993, provides substantial evidence that suggests vascular risk factors (VRF) play a critical role in the development of cognitive decline and AD during aging.
Why it matters
This article proposes that vascular risk factors play a critical role in cognitive decline and Alzheimer's disease, and proposes a preliminary randomized clinical study using carotid Doppler ultrasound, echocardiography, and ankle-brachial index to screen cognitively healthy middle-aged individuals. It suggests that detecting and treating vascular risk factors could prevent or slow disease progression, but this is a proposal, not established prevention.
-
Alzheimer's disease is the most common dementia in the elderly, and the potential of peripheral biochemical markers as complementary tools in the neuropsychiatric evaluation of these patients has claimed further attention.
Why it matters
This study measured serum S100B and NSE levels in 54 Alzheimer's disease patients and 66 community-dwelling elderly people. It is a biomarker comparison and does not test any treatment, cure, or prevention.
-
All biomarkers were sensitive to the diagnostic group.
-
The Free and Cued Selective Reminding Test (FCSRT) is a verbal episodic memory test used to identify patients with mild Alzheimer's disease (AD).
-
We investigated the performance of FDG PET using an automated procedure for discrimination between Alzheimer's disease (AD) and controls, and studied the influence of demographic and technical factors.
Why it matters
This study tested whether FDG PET brain scans can tell apart people with Alzheimer's disease from people without it, using an automated method. The scans were analyzed in two separate groups of participants, which helps show whether the method works consistently across different populations.
-
Coptidis Rhizoma and its isolated alkaloids are reported to possess a variety of activities, including neuroprotective and antioxidant effects.
Why it matters
Several alkaloids from Coptidis Rhizoma inhibited acetylcholinesterase and butyrylcholinesterase in laboratory assays, and two also showed activity against BACE1. These are test-tube results only and do not show that these compounds treat or prevent Alzheimer's disease in people.
-
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive decline in multiple cognitive domains.
Why it matters
In brain tissue from four people with early Alzheimer's disease, eight proteins were found to be significantly nitrated in the inferior parietal lobule. This is a very small tissue study of possible disease mechanisms and does not show any treatment, cure or prevention.
-
Atrophy of hippocampus and alteration of resting eyes-closed electroencephalographic (EEG) rhythms represent important features of mild cognitive impairment (MCI) and Alzheimer's disease (AD).
-
In this study event related coherence of patients with Alzheimer type of dementia (AD) was analyzed by using a visual oddball paradigm as stimuli.
Why it matters
This small EEG study found reduced event-related brain wave coherence in people with mild Alzheimer's disease compared with healthy controls, with some differences between treated and untreated patients. It describes a brain activity measurement and does not test whether any treatment improves symptoms or changes the disease course.
-
This automated method can serve as an alternative to manual tracing and may thus prove useful in assisting with the diagnosis of AD.
-
Alzheimer and a number of other neurodegenerative diseases are characterized by the presence of reactive microglia and reactive astrocytes in association with the lesions.
Why it matters
This review describes activated microglia as either pro-inflammatory or anti-inflammatory, with evidence that microglial phagocytosis is more powerful in the anti-inflammatory state. It reports no treatment, cure, or prevention for Alzheimer's disease.
-
This paper discusses the effects of curcumin on patients with Alzheimer's disease (AD).
Why it matters
This overview states that curcumin has a potential role in the prevention and treatment of Alzheimer's disease based on its antioxidant and anti-inflammatory properties. It presents potential rather than demonstrated clinical benefit, so it does not show that curcumin treats or prevents the disease.
-
43/100
In addition, we examined whether anosognosia had an impact on the agreement between patient and informant ratings of QoL and whether anosognosia, dementia severity, depression and behavioural symptoms were significantly correlated to QoL in early AD.
Why it matters
This study of 48 patients with very early Alzheimer's disease compared quality-of-life ratings given by patients versus informants and examined whether anosognosia affected agreement between them. The provided text does not report the findings, so it is unclear how patient and informant ratings differed.
-
Costs of care in patient with AD are high and related to dementia severity as well as presence of behavioural disturbances.
Why it matters
In 272 Alzheimer's disease patients across four Nordic countries, total annual costs rose sharply with disease severity, from mild to severe dementia. Informal care costs made up about a third of total costs and also increased significantly with disease severity.
-
Pathophysiologic hypotheses for Alzheimer's disease (AD) are centered on the role of the amyloid plaque Abeta peptide and the mechanism of its derivation from the amyloid precursor protein (APP).
Why it matters
This paper considers the potential role of Nogo-66 receptor mechanisms in Alzheimer disease and reports that both Nogo and NgR are mislocalized in Alzheimer brain samples. It is a mechanistic consideration and does not offer a treatment, cure or prevention.
-
Hippocampal atrophy is not only a characteristic of Alzheimer's disease but also occurs in FTLD.
-
This paper investigates factors that underlie reduced informative content and lack of reference in the discourse of patients with Alzheimer's Type Dementia (DAT).
Why it matters
This study shows that people with Alzheimer's type dementia are less effective at making themselves understood than their word-finding problems alone would predict. It offers no treatment or prevention, only insight into how communication breaks down.
-
There is evidence to suggest that certain shared features exist in the pathogenesis of vascular disease and Alzheimer disease (AD) in the general population.
Why it matters
This review discusses shared features of vascular disease and Alzheimer disease, noting that although nearly all adults with Down syndrome over 40 develop Alzheimer neuropathology, vascular disease such as atheromas is less common in them. It proposes that studying Down syndrome may help identify common pathogenic links but reports no treatment or cure.
-
Plasma and serum biochemical markers proposed for Alzheimer disease (AD) are based on pathophysiologic processes such as amyloid plaque formation [amyloid beta-protein (A beta), A beta autoantibodies, platelet amyloid precursor protein (APP) isoforms], inflammation (cytokines), oxidative stress (vitamin E, isoprostanes), lipid metabolism (apolipoprotein E, 24S-hydroxycholesterol), and vascular disease [homocysteine, lipoprotein (a)].
Why it matters
This review concludes that most proteins or metabolites measured in plasma or serum so far are at best biological correlates of Alzheimer's disease and lack the sensitivity or specificity needed for diagnosis or for tracking response to therapy. It notes that combining panels of markers or using proteomics may help discover useful profiles, but no such test is established.
-
Glial fibrillary acidic protein (GFAP) is considered to be a highly specific marker for glia.
Why it matters
This study found that neurons in the hippocampus can express GFAP, coded by novel splice forms, and that this expression is associated with Alzheimer pathology. It describes a biological finding and reports no treatment, cure or prevention.
-
Previously, we reported that morning bright light therapy improved sleep time and cognitive function in Alzheimer type of dementia.
Why it matters
This small double-blind study gave 3 mg of melatonin or a placebo to 20 people with Alzheimer type dementia for 4 weeks to see effects on sleep-wake rhythm and cognitive and non-cognitive function. The text provided does not report the results, so no conclusion about treating, curing, or preventing Alzheimer's disease can be drawn from it.
-
The ability to detect patients at high risk for Alzheimer type dementia among those with minor cognitive impairment increases when data on age and memory function are combined with measures of medial temporal lobe atrophy.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults
- Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum
- Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia
- Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial
- Bildgebungsanomalien bei Alzheimer-Therapie mit Lecanemab
- Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4
- Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
- The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study
- Characterizing Exposure to Traffic‐Related Air Pollution in a Diverse Alzheimer’s Disease Research Center Cohort
- High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients